Hencheng Zhu

Dr. Hencheng Zhu


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 September 2020 in The FASEB Journal
Verified
Journal Article
Open access
PDF file
ZPZhou Pan
Zhou Pan
KYKang Yang
Kang Yang
HWHuibo Wang
Huibo Wang
YXYusha Xiao
Yusha Xiao
MZMing Zhang
Ming Zhang
HZHencheng Zhu
Hencheng Zhu
Renal fibrosis, which is characterized by excessive extracellular matrix (ECM) accumulation in the renal tubulointerstitium, can lead to chronic kidney disease (CKD). The role of microfiber‐associated protein 4 (MFAP4), which is an ECM protein that interacts with elastin and collagen, in renal fibrosis has not been investigated. The aim of this study was to examine the role of MFAP4 in the pathogenesis of renal fibrosis and the underlying mechanism using in vivo and in vitro models. The MFAP4 −/− mice were subjected to unilateral ureteral obstruction (UUO) to elucidate the role of MFAP4 in renal fibrosis in vivo. Compared to the wild‐type mice, the MFAP4 −/− mice exhibited decreased protein expression of p‐p65 and p‐IKBα and ECM deposition after UUO. The MFAP4 −/− mice exhibited attenuated nuclear translocation of p65 (the hub subunit of nuclear factor (NF)‐κB signaling pathway), suppressed activation of transforming growth factor (TGF)‐β/Smad pathways, and downregulated expression of fibronectin, collagen I, and plasminogen activator inhibitor‐1. The knockdown of MFAP4 mitigated the TGF‐β‐induced upregulated expression of fibronectin, collagen I, and plasminogen activator inhibitor‐1 in the human proximal tubular epithelial cells (HK‐2). Compared to the HK‐2 cells transfected with sh‐MFAP4, the HK‐2 cells co‐transfected with sh‐MFAP4 and Ad‐MFAP4 exhibited severe inflammatory response and increased fibrosis‐related proteins expression. Mechanistically, the knockdown of MFAP4 inhibited the activation of NF‐κB and TGF‐β/Smad signaling pathways and downregulated the expression of fibrosis‐related proteins. The findings of this study indicate that MFAP4 is involved in UUO‐induced renal fibrosis through regulation of NF‐κB and TGF‐β/Smad pathways.

6 October 2023 in Aging
Verified
Journal Article
Open access
PDF file
ZPZhou Pan
Zhou Pan
JHJing Huang
Jing Huang
HSHuajie Song
Huajie Song
YXYusha Xiao
Yusha Xiao
TLTing Liu
Ting Liu
KYKang Yang
Kang Yang
Autophagy has been increasingly recognized as a critical regulatory mechanism in the maintenance of cellular homeostasis. A previous study showed that phospholipase C-like protein 1 (PLCL1) is associated with lipid metabolism in renal cell carcinoma (RCC). However, it is unclear whether PLCL1 regulates autophagy, thereby influencing the progression of RCC. Bioinformatics analysis of five microarray datasets revealed that expression of PLCL1 is decreased in tumours and is positively correlated with prognosis in RCC patients. Three independent public datasets, clinical RCC tissues and RCC cell lines, were validated using real-time qPCR, western blotting and immunohistochemistry. Using wound healing and transwell assays, we observed that elevated PLCL1 levels decreased the migratory distance and the invasive number of 786-O and ACHN cells, but PLCL1 knockdown reversed these changes in 769P cell lines compared to those in controls. The results of flow cytometry analysis indicated that PLCL1 promotes apoptosis. Moreover, transcriptional analysis based on stable overexpression of PLCL1 in 786-O cells revealed that PLCL1 is related to autophagy, and western blotting and autophagic experimental results further verified these findings. Mechanistic investigations confirmed that PLCL1 activates the AMPK/mTOR pathway and interacts with decidual protein induced by progesterone (DEPP). Collectively, our data suggest that PLCL1 functions as a suppressor of RCC progression by activating the AMPK/mTOR pathway, interacting with DEPP, initiating autophagy and inducing apoptosis. PLCL1 may be a promising therapeutic target for the diagnosis and treatment of ccRCC patients.

1 September 2024 in Translational Andrology and Urology
Verified
Journal Article
Open access
PDF file
JJJiahao Jiang
Jiahao Jiang
FXFei Xiao
Fei Xiao
LYLanxin Yang
Lanxin Yang
YZYan Zeng
Yan Zeng
JCJing Chen
Jing Chen
LLlingqi liu
lingqi liu
Background: Chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) is a common male urological disease characterized by chronic pelvic pain and various discomforts. Astaxanthin (AST) has multiple functions, including anti-inflammatory property, but it is unclear whether AST plays a key role in CP/CPPS and how it works. This study aimed to investigate the protective effect of AST on CP/CPPS in rats and the underlying mechanism. Methods: A CP/CPPS rat model was induced by intraprostatic injection of carrageenan and the blood specimens and prostates were harvested for further research after oral administration of AST for 4 weeks. Results: Tactile allodynia test showed that AST ameliorated chronic pelvic pain in a dose-depended manner. In addition, histological evaluation indicated that AST alleviated CP/CPPS rat prostate histological inflammation. Meanwhile, AST suppressed the expression of proinflammatory cytokines, including interleukin-1β (IL-1β), IL-6, IL-8, and tumor necrosis factor-α (TNF-α). Besides, AST inhibited the activities of prostaglandin E2 (PGE2) and cyclooxygenase 2 (COX2). Furthermore, AST decreased the activation of the nuclear factor-κB (NF-κB) signaling pathway. Conclusions: Our study has shown that AST exerts an anti-inflammatory and protective effect against CP/CPPS and the function is mediated at least through the suppression of NF-κB signaling pathway. These results provide evidence of AST as the potential agents for the treatment of CP/CPPS.

25 October 2024 in Archives of Biochemistry and Biophysics
Verified
Journal Article
Closed access
FXFei Xiao
Fei Xiao
YGYi Guan
Yi Guan
TLTing Liu
Ting Liu
YZYan Zeng
Yan Zeng
HZHencheng Zhu
Hencheng Zhu
KYKang Yang
Kang Yang

13 March 2026 in Discover Oncology
Verified
Journal Article
Open access
PDF file
MHMu He
Mu He
WHWei Hu
Wei Hu
YGYi Guan
Yi Guan
WSWenjing Shu
Wenjing Shu
YLYan Leng
Yan Leng
KYKang Yang
Kang Yang
Objective Clear cell renal cell carcinoma (ccRCC) is the most common subtype of renal cell carcinoma. Cuproptosis is a new type of programmed cell death that is mediated by protein lipid acylation and is closely linked to mitochondrial metabolism. Methods The Cancer Genome Atlas (TCGA) database provided us with RNA-Seq data together with the related clinical and prognostic information. Using univariate Cox, 135 prognostic lncRNAs associated with cuproptosis were identified for use in prognostic model construction. Multivariate Cox analysis was subsequently used to further integrate these lncRNAs. We used subject operating characteristic (ROC) curve analysis and Kaplan-Meier (K-M) survival curve analysis to assess the model’s prognostic ability. In order to predict immune escape and potential therapeutic drugs in the two groups, we also looked at the differences in immunological and tumor mutational burden between the high- and low-risk groups. The quantitative polymerase chain reaction (Q-PCR) was then used to validate the risk model. Results The lncRNA profile linked to cuproptosis is used to divide patients into two risk categories, with the lower risk group having a better prognosis. The tumor mutational burden was larger, immune escape was more likely to occur, and immunotherapy results were generally worse in the high-risk group. The traditional chemotherapeutic medications sunitinib, AKT inhibitor VIII, rapamycin, and lapatinib were more effective in low-risk individuals. Six prognostic lncRNAs were ultimately confirmed in human cell lines, including HK-2, ACHN, 769-P, and CAKI-1. Conclusions A risk model based on six cuproptosis-related lncRNAs has a high predictive value for ccRCC and might be a medical target for cuproptosis.